Andrew Philips

Andrew Philips

Company: AbbVie

Job title: Director of Next Generation Drug Conjugates


Looking at BCL-XL Inhibitor Antibody Drug Conjugates: A Novel Approach to Increase the Therapeutic Index of ADCs 3:00 pm

Reviewing the narrow therapeutic index of cytotoxic-based ADCs placing limits on their clinical utility Describing the preclinical development and characterization of BCL-XL inhibitor ADCs and how they expand TI Evaluating preclinical characterization and status of the lead program mirzotamab clezutoclax (ABBV-155)Read more

day: Day Two

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.